Epigenomics AG / Key word(s): Capital Increase 28.05.2015 11:25 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Ad Hoc Announcement pursuant to Sec. 15 WpHG (German Securities Trading Act) Epigenomics […]
Year: 2015
28. May 2015
Epigenomics AG: Epigenomics AG Places Maximum Number of New Shares in Capital Increase with Pre-emptive Rights
Read more
28. May 2015
Epigenomics AG: Epigenomics AG Successfully Completes Capital Increase
Epigenomics AG / Key word(s): Capital Increase 2015-05-28 / 11:25 Press release Epigenomics AG Successfully Completes Capital Increase Total gross proceeds of EUR 4.9 million raised in a rights issue Transaction significantly over-subscribed Use of proceeds to finance market introductory measures for Epi proColon(R) in the U.S. Not for distribution in the United States Berlin […]
12. May 2015
Epigenomics AG Announces Q1 2015 Financial Results and Reports on Operational Highlights
Epigenomics AG / Key word(s): Quarter Results/Quarter Results 2015-05-12 / 08:30 Press release Epigenomics AG Announces Q1 2015 Financial Results and Reports on Operational Highlights – Epigenomics reaches 99.5% adherence for Epi proColon(R) in the ADMIT Trial – BioChain starts to commercialize Epi proColon(R) in China – Epigenomics receives EUR 2.8 million grant from European […]
11. May 2015
Ad Hoc Announcement pursuant to Sec. 15 WpHG (German Securities Trading Act): Epigenomics AG Announces Capital Increase up to EUR 5M
Epigenomics AG / Key word(s): Capital Increase/Miscellaneous 11.05.2015 08:38 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Not for distribution in the United States of America Berlin, Germany, May 11, […]
08. May 2015
Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study
Epigenomics AG / Key word(s): Study/Study results 08.05.2015 09:04 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study Berlin, Germany, […]
08. May 2015
Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study
Epigenomics AG / Key word(s): Study/Study results 2015-05-08 / 09:06 Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study Berlin, Germany, May 8, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces results from the ADMIT trial (ADherence to Minimally Invasive Testing – NCT02251782) for its non-invasive blood-based test for colorectal […]